Skip to content
MARKETS / NASDAQ / PACB
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · MID CAP

Pacific Biosciences of California, Inc. PACB

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$160.0M
▲ 3.9% YoY
$-546.4M
$-113.9M
In brief

What this company does

It designs, develops and manufactures advanced sequencing solutions, including its HiFi long-read sequencing technology, addressing applications in human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. As of December 31, 2025, it had 485 full-time employees, most of whom are based in California. Its key manufacturing and service facility, which has received ISO 13485 and ISO 9001 certifications, is located in Menlo Park, California. As of December 31, 2025, it owned or held exclusive licenses to 450 issued U.S. patents and 318 issued foreign patents, along with pending applications in both. For the years ended December 31, 2025, 2024, and 2023, no customer accounted for 10% or more of its total revenue. It markets its products through a global sales force and through distribution partners in Australia, parts of Asia, Europe, the Middle East, Africa, Central America and South America.

Written from the business description in PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth
USD 160.0M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 160.0 · Net income -546.4
80M160M-200M-400M200920112013201520172019202120232025
Compound annual growth
+7.6%
+15.2%
+5.6%
+35.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +15.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−341 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -346.2% · Net -341.5%
-20000%-40000%-60000%200920112013201520172019202120232025
ROE
FY2025 · ROE -213.5%
-100%-200%200920112013201520172019202120232025

Each USD of equity lost 213 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -113.9
-100M-200M200920112013201520172019202120232025
Net buybacks $ Dividends $
FY2009 · Dividends — · Net buybacks -303000.0
-2000002009

Total assetsUSD 784.1M
EquityUSD 5.3M
CashUSD 63.7M
Current ratio5.15×

Equity funds 1% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.20.20.20.10.10.10.10.10.10.10.10.10.00.00.00.00.0
Operating income $B−0.6−0.5−0.3−0.3−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1··
EBITDA $B−0.5−0.5−0.3−0.3−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1··
Income tax $B0.00.0−0.00.0−0.1············
Net income $B−0.5−0.3−0.3−0.3−0.20.0−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.1−0.1
Free cash flow $B−0.1−0.2−0.3−0.3−0.10.0−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1
EPS, diluted $−1.82−1.59−1.21−1.40−0.890.17−0.55−0.76−0.87−0.83−0.42−0.94−1.26−1.69−2.03−14.10−173.03
Dividend / sh $0.000.000.000.000.000.000.000.000.000.000.000.000.00····
Payout %·················
ROE %−213.5−51.3−48.5−46.4−32.215.1−99.6−102.5−108.0−94.0−49.3−106.6−88.8−62.8−46.4−272.8·
Shares out B0.300.290.270.230.220.190.150.150.120.090.080.070.070.060.000.05·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image